Androgen receptor-mediated upregulation of quaking affects androgen receptor-related prostate cancer development and anti-androgen receptor therapy

被引：5

作者：

Zhang, Keke ^{[1
]}

Yan, Fei ^{[1
]}

Lei, Xiaoying ^{[2
]}

Wei, Di ^{[1
]}

Lu, Huanyu ^{[2
]}

Zhu, Zheng ^{[1
]}

Xiang, An ^{[2
]}

Ye, Zichen ^{[2
]}

Wang, Li ^{[2
]}

Zheng, Wanxiang ^{[1
]}

Li, Xi'an ^{[1
]}

Yuan, Jiarui ^{[3
]}

Lu, Zifan ^{[2
]}

Yuan, Jianlin ^{[1
]}

机构：

[1] Fourth Mil Med Univ, Xijing Hosp, Dept Urol, 15 Changle Xi Rd, Xian 710032, Shaanxi, Peoples R China

[2] Fourth Mil Med Univ, Sch Pharm, Dept Pharmacogen, State Key Lab Canc Biol, 169 Changle Xi Rd, Xian 710032, Shaanxi, Peoples R China

[3] Univ Washington, Dept Biochem, Seattle, WA 98195 USA

来源：

MOLECULAR MEDICINE REPORTS | 2018年 / 17卷 / 06期

基金：

美国国家科学基金会;

关键词：

androgen receptor; prostate-specific antigen; quaking; prostate cancer; drug sensitive; EXPRESSION; RNA; QKI; RESISTANCE; CARCINOMA; VARIANT; HSP90;

D O I：

10.3892/mmr.2018.8882

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The androgen receptor (AR) has a crucial role in prostate cancer. RNA-binding protein-mediated post-transcriptional regulation is important in the initiation and development of cancer. The present study attempted to elucidate the mutual association of AR and RNA-binding protein quaking (QKI) in the development of prostate cancer. Dual-luciferase reporter demonstrated that AR can positively regulate the expression of QKI in prostate cancer cell lines due to its effective transcription regulating function. In addition, QKI may increase expression of AR by heat shock protein 90, which is a coactivator of AR, and silencing QKI can increase the sensitive of Casodex, which is an antagonist of AR in castration-resistant prostate cancer. This may be a new strategy for advanced prostate cancer.

引用

页码：8203 / 8211

页数：9

共 50 条

[41] Advances in Androgen Receptor Targeted Therapy for Prostate Cancer
Ahmed, Alia
Ali, Shadan
Sarkar, Fazlul H.
[J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2014, 229 (03) : 271 - 276
[42] The androgen receptor: a potential target for therapy of prostate cancer
Santos, AF
Huang, H
Tindall, DJ
[J]. STEROIDS, 2004, 69 (02) : 79 - 85
[43] The evolution of prostate cancer therapy: targeting the androgen receptor
Aragon-Ching, Jeanny B.
[J]. FRONTIERS IN ONCOLOGY, 2014, 4
[44] PROSTATE-CANCER AND THE ANDROGEN RECEPTOR
COETZEE, GA
ROSS, RK
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (11) : 872 - 873
[45] Androgen receptor mutations in prostate cancer
Barrack, ER
[J]. MOUNT SINAI JOURNAL OF MEDICINE, 1996, 63 (5-6): : 403 - 412
[46] Androgen receptor mutations in prostate cancer
Marcelli, M
Ittmann, M
Mariani, S
Sutherland, R
Nigam, R
Murthy, L
Zhao, YL
DiConcini, D
Puxeddu, E
Esen, A
Eastham, J
Weigel, NL
Lamb, DJ
[J]. CANCER RESEARCH, 2000, 60 (04) : 944 - 949
[47] Androgen receptor signaling in prostate cancer
Zoran Culig
Frédéric R. Santer
[J]. Cancer and Metastasis Reviews, 2014, 33 : 413 - 427
[48] Role of the androgen receptor in prostate cancer
Lamb, Alastair D.
Neal, David E.
[J]. TRENDS IN UROLOGY & MENS HEALTH, 2013, 4 (03) : 26 - 30
[49] Androgen receptor coactivators and prostate cancer
Agoulnik, Irina U.
Weigel, Nancy L.
[J]. HORMONAL CARCINOGENESIS V, 2008, 617 : 245 - 255
[50] The androgen receptor and prostate cancer invasion
Bonaccorsi, L
Muratori, M
Marchiani, S
Forti, G
Baldi, E
[J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2006, 246 (1-2) : 157 - 162

← 1 2 3 4 5 →